Skip to main content
NMRA logo

Neumora Therapeutics, Inc.

NMRANASDAQHealthcareBiotechnology

$0.47Today:- (-)1Y −75.32%

As of Oct 16, 2026 close

Market cap
$79.06M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.32$3.65
Volume (live)
-
Avg. volume (3M)
2.16M

Neumora Therapeutics (NMRA) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Neumora Therapeutics used $206.44M of cash in operating activities. Free cash flow was −$206.44M.

Neumora Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Neumora Therapeutics, Inc. (NMRA) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-236.93-243.79-235.93-130.90-237.31-99.27
Depreciation & Amortization0.210.630.670.590.540.11
Deferred Income Tax0.000.000.000.00-0.053.08
Stock Based Compensation29.8839.9917.248.304.271.68
Change in Working Capital-0.4422.64-8.90-6.95-0.96-3.12
Change in Accounts Payable0.072.87-0.58-1.25-0.76-4.67
Change in Other Working Capital-0.513.31-8.32-5.70-6.761.55
Other Operating Activities0.843.3163.6414.06158.043.99
Net Cash from Operating Activities-206.44-182.94-163.28-114.90-75.42-26.76
Investing Activities
Capital Expenditures0.00-0.78-0.12-0.51-0.82-1.30
Acquisitions0.00-0.780.000.000.002.81
Purchases of Investments-85.80-312.22-109.07-226.370.000.00
Sales/Maturities of Investments251.17242.44178.1771.870.000.00
Other Investing Activities3.150.00-4.59-13.000.00-12.75
Net Cash from Investing Activities168.52-70.5664.39-168.01-0.82-11.24
Financing Activities
Debt Repayment57.160.000.000.000.0055.91
Common Stock Issued19.9313.69233.380.003.473.19
Common Stock Repurchased0.000.00-0.490.000.000.00
Other Financing Activities0.007.91-0.95115.74-1.21-0.90
Net Cash from Financing Activities77.0921.60231.94115.74293.51230.10
Summary
Net Change in Cash39.17-231.89133.05-167.17217.27192.10
Cash at Beginning of Period143.36375.25242.21409.37192.100.00
Cash at End of Period182.53143.36375.25242.21409.37192.10
Free Cash Flow-206.44-182.94-163.40-115.41-76.24-28.06
Supplemental Disclosures
Income Taxes Paid-0.47----

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Neumora Therapeutics Cash Flow

What is Neumora Therapeutics's free cash flow?

Neumora Therapeutics had negative free cash flow of $206.44M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Neumora Therapeutics pay dividends or buy back shares?

Neumora Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition